Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax-share withholding

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported equity compensation activity involving restricted stock units and common stock. On the transaction date, 39,059 restricted stock units vested, each representing a right to receive one share of common stock, and were converted into 39,059 shares of Iovance common stock.

To cover mandatory tax withholding on the vesting, 18,360 shares of common stock were withheld by the company at a price of $4.58 per share. This withholding was not an open market sale of securities. After these transactions, Puri directly held 239,230 shares of common stock and 78,131 restricted stock units, with remaining RSUs scheduled to vest in equal quarterly installments.

Insider Trade Summary

39,059 shares exercised/converted

Mixed 3 txns

Insider Puri Raj K.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	39,059	$0.00	--
Exercise	Common Stock	39,059	$0.00	--
Tax Withholding	Common Stock	18,360	$4.58	$84K

Holdings After Transaction: Restricted Stock Units — 78,131 shares (Direct); Common Stock — 257,590 shares (Direct)

Footnotes (1)

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Represents the common stock remaining after deducting the common stock withheld for taxes. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The remaining RSUs will vest in equal quarterly installments. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puri Raj K.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/05/2026		M		39,059	A	$0	257,590	D
Common Stock(2)	03/05/2026		F		18,360	D	$4.58	239,230(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	03/05/2026		M			39,059	(5)	(5)	Common stock	39,059	$0.00	78,131(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Raj K. Puri	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IOVANCE BIOTHERAPEUTICS (IOVA) report for Raj K. Puri?

Raj K. Puri reported vesting of 39,059 restricted stock units that converted into the same number of common shares. The filing also shows 18,360 shares of common stock withheld to satisfy mandatory tax obligations related to this vesting event.

Did the IOVA insider Form 4 include any open market stock sales?

The Form 4 states that shares were withheld to satisfy tax withholding on vested RSUs and clarifies this was not an open market sale. The disposition coded “F” reflects tax-related share withholding by the company rather than a market transaction.

How many IOVANCE BIOTHERAPEUTICS shares does Raj K. Puri hold after these transactions?

After the reported transactions, Raj K. Puri directly holds 239,230 shares of Iovance common stock. He also holds 78,131 restricted stock units, representing a contingent right to receive the same number of common shares as they vest over time.

What do the restricted stock units (RSUs) in the IOVA Form 4 represent?

Each RSU reported in the filing represents a contingent right to receive one share of Iovance common stock. The Form 4 notes that the remaining RSUs from the March 5, 2025 grant will vest in equal quarterly installments going forward.

Why were 18,360 IOVA shares disposed of in Raj K. Puri’s Form 4?

The 18,360 common shares were withheld by Iovance to cover mandatory tax withholding triggered by RSU vesting. A footnote explains this transaction is solely for tax purposes and is not treated as an open market sale of securities.

What role does Raj K. Puri hold at IOVANCE BIOTHERAPEUTICS (IOVA)?

Raj K. Puri is identified in the Form 4 as the company’s Chief Regulatory Officer. The reported transactions involve his direct ownership of restricted stock units and common stock, reflecting equity-based compensation and related tax withholding activity.